Compare INFU & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFU | RNA |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.1M | 227.6M |
| IPO Year | 2005 | 2025 |
| Metric | INFU | RNA |
|---|---|---|
| Price | $9.28 | $13.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $15.00 | ★ $69.26 |
| AVG Volume (30 Days) | 96.1K | ★ 591.3K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 181.82 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $143,436,000.00 | N/A |
| Revenue This Year | $2.89 | $88.12 |
| Revenue Next Year | $7.66 | $18.11 |
| P/E Ratio | $30.00 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $4.61 | $11.95 |
| 52 Week High | $11.04 | $73.06 |
| Indicator | INFU | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 11.66 |
| Support Level | $8.52 | $13.06 |
| Resistance Level | $9.89 | $72.75 |
| Average True Range (ATR) | 0.40 | 0.58 |
| MACD | -0.09 | 2.13 |
| Stochastic Oscillator | 40.52 | 71.57 |
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.